Recently, the optimism surrounding blockbuster weight-loss drugs has propelled a few mega-cap health care stocks to dizzying valuations. But the opportunities for profitable growth in the Health Care sector go far beyond headline-makers and market darlings. Join Harding Loevner Health Care analyst David Glickman as he explores some of the newer advancements shaping the future of health care—from the promise of mRNA technology in oncology to biologic drug contract manufacturing dynamics, AI in health care, and next generation innovations still flying under the radar.
ADMIN